BRAF and pancreatic neoplasm: One case reported that a patient with stage IV pancreatic cancer with BRAF V600E mutation received combined targeted therapy with dabrafenib and trametinib, but the patient died of acute abdomen (29) after only 19 days of treatment, while the therapeutic effect of vemurafenib on advanced pancreatic cancer was not observed in another case (30).